<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654626</url>
  </required_header>
  <id_info>
    <org_study_id>KBP7072-1-002</org_study_id>
    <nct_id>NCT02654626</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-controlled, Sequential Parallel-Group and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, placebo-controlled, sequential parallel-group and
      multiple ascending dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics
      of KBP 7072 in healthy subjects. The safety will be assessed at each dose level before
      progressing to the next higher dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (i.e., number of participants with adverse events, abnormal vital signs, clinical laboratory findings, 12-lead ECGs and physical examinations) in healthy subjects</measure>
    <time_frame>up to 17 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) in healthy subjects</measure>
    <time_frame>up to 10 days</time_frame>
    <description>on Day 1 (first dose): pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours post dose; on Days 4, 7, 8, and 9: pre-dose (within 30 minutes prior to dosing); on Day 10 (last dose): pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>KBP-7072: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-7072 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-7072 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-7072 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-7072 and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-7072</intervention_name>
    <description>Drug Intervention</description>
    <arm_group_label>KBP-7072: Cohort 1</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 2</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 3</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>KBP-7072: Cohort 1</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 2</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 3</arm_group_label>
    <arm_group_label>KBP-7072: Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subject

          -  Are between the ages of 18 and 55 years (inclusive);

          -  Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg.

        Exclusion Criteria:

          -  Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity;

          -  Known or suspected malignancy;

          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C (HCV) antibody;

          -  Positive pregnancy test result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Zhang</last_name>
    <role>Study Director</role>
    <affiliation>KBP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage Laboratories, Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

